TheraSonic proudly announces a fundraising of €1 million to finance the development of its robotic medical device designed to improve drug delivery in the brain through the use of focused ultrasound.

This fundraising is led by the European venture studio M2care, created on the initiative of Mérieux Développement, specialized in healthtech, and associated with the project for a year in pre-creation. Gustave Roussy Transfert, a company dedicated to innovation and technology transfer, a subsidiary of Gustave Roussy, Europe’s leading cancer fighting center, also enters the capital of TheraSonic to enable access to unique clinical expertise to ensure the technological transition to the first patients as quickly as possible.